Phase 2 N=8 Treatment

Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine

Opioid-use Disorder

Bottom Line

View on ClinicalTrials.gov: NCT04192370 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2023

Primary outcome: Primary: Change in Cue-induced Cravings and Anxiety After 3 Days of Cannabidiol Administration — 3.2; 0.4 score on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Cannabidiol 600mg (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Brigham and Women's Hospital
Primary completion: Dec 2021

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Cue-induced Cravings and Anxiety After 3 Days of Cannabidiol Administration	3.2; 0.4	—

Summary

The purpose of this week-long study is to determine the impact of cannabidiol on cue-induced cravings among individuals with opioid use disorder who are stable on sublingual buprenorphine treatment.

Eligibility Criteria

Inclusion Criteria

Diagnosis of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) opioid use disorder, severe
Currently in treatment with methadone or buprenorphine

Exclusion Criteria

Requiring level of care higher than outpatient treatment for alcohol, sedative/hypnotics, or stimulants
Any current mood episode requiring level of care higher than outpatient treatment
History of psychotic disorder or bipolar disorder
Currently pregnant
Hepatic liver enzymes greater than 3x upper normal limit
Hypersensitivity to cannabinoids or sesame oil (cannabidiol solution comes in sesame oil emulsion)
Currently taking any medications with known significant pharmacokinetic interactions with CBD

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04192370). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.